Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Net Cash Flow (2023 - 2025)

Immunome (IMNM) has disclosed Net Cash Flow for 3 consecutive years, with $380.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 3217.32% year-over-year to $380.8 million, compared with a TTM value of $510.2 million through Dec 2025, up 1042.19%, and an annual FY2025 reading of $510.2 million, up 1042.19% over the prior year.
  • Net Cash Flow was $380.8 million for Q4 2025 at Immunome, up from $128.8 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $380.8 million in Q4 2025 and bottomed at -$113.6 million in Q2 2025.
  • Average Net Cash Flow over 3 years is $52.8 million, with a median of $16.1 million recorded in 2023.
  • The sharpest move saw Net Cash Flow tumbled 1637.53% in 2024, then skyrocketed 3217.32% in 2025.
  • Year by year, Net Cash Flow stood at $8.0 million in 2023, then tumbled by 251.99% to -$12.2 million in 2024, then surged by 3217.32% to $380.8 million in 2025.
  • Business Quant data shows Net Cash Flow for IMNM at $380.8 million in Q4 2025, $128.8 million in Q3 2025, and -$113.6 million in Q2 2025.